
Tectonic Therapeutic, Inc. (TECX) Stock Ticker
TECX right now
Market factors today
Unlock the full TECX picture
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
TECX stock facts
| Ticker symbol | TECX |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $446.6M |
| CEO | Alise S. Reicin |
| Employees | 60 |
| Headquarters | Watertown, MA, US |
| IPO date | 2018-06-21 |
| Website | tectonictx.com |
What you can see for TECX on Tickr
Live TECX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the TECX report.
Rankings
FAQ
What is the ticker symbol for Tectonic Therapeutic, Inc.?
The ticker symbol for Tectonic Therapeutic, Inc. is TECX, listed on the NASDAQ Global Market.
What is TECX?
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted…